Hapalosin
Hapalosin is a multidrug resistance reversal agent and chemosensitizer with mild cytotoxicity against cancer cells. Hapalosin inhibits the ATP-dependent drug efflux pump function of P-glycoprotein and antagonizes multidrug resistance-associated proteins. Hapalosin reverses multidrug resistance mediated by P-glycoprotein and multidrug resistance-associated proteins, increases the intracellular accumulation of drugs transported by P-glycoprotein, and enhances the cytotoxicity of these drugs against cancer cells overexpressing P-glycoprotein. Hapalosin can be used in the research of multidrug-resistant cancers.
For research use only. We do not sell to patients.
- CAS No.: 159542-04-8
- Formula: C28H43NO6
- Molecular Weight:489.64
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HL-60 | EC50 |
0.7 μg/mL
Compound: hapalosin
|
Effective concentration against HL-60/ADR cells using MRP-mediated MDR assay using 2 nM vincristine which results in 50% of the cells being killed in the presence of particular cytotoxic drug.
Effective concentration against HL-60/ADR cells using MRP-mediated MDR assay using 2 nM vincristine which results in 50% of the cells being killed in the presence of particular cytotoxic drug.
|
[PMID: 9526572] |
In Vitro
Hapalosin (1-6 µg/mL; 48 h) reverses P-gp-mediated multidrug resistance (MDR) in MCF-7/ADR cells, with an EC50 of 1 µg/mL; meanwhile, the compound has an IC20 of 6 µg/mL for intrinsic cytotoxicity against these cells[1].
Hapalosin (0.7-6 µg/mL; 48 h) reverses MRP-mediated multidrug resistance (MDR) in HL-60/ADR cells, with an EC50 of 0.7 µg/mL; meanwhile, the IC20 for its intrinsic cytotoxicity against these cells is 6 µg/mL[1].
Hapalosin (60 min) effectively increases the intracellular accumulation of [3H]-Vinblastine (HY-13780) in MCF-7/ADR cells, indicating that it inhibits P-gp-mediated drug efflux[1].
Hapalosin (20 μM; 90 min) increases the accumulation of [3H]-Vinblastine and [3H]-Paclitaxel (HY-B0015) in SKVLB1 cells by inhibiting the P-glycoprotein efflux pump; at a concentration of 20 μM, the accumulation of [3H]-Paclitaxel increases by 440% compared with the control group, while this compound does not affect drug accumulation in SKOV3 cells[2].
Hapalosin (2.5-12.5 μM; 48 h) selectively enhances the cytotoxicity of chemotherapeutic drugs transported by P-glycoprotein against MCF-7/ADR cells at concentrations ≥ 2.5 μM, and completely reverses P-glycoprotein-mediated multidrug resistance to vinblastine in these cells at a concentration of 5 μM[2].
Hapalosin exhibits cytotoxicity against KB, LoVo and MCF-7/ADR cells, with IC50 values of 2.5 μg/mL, 2 μg/mL and 5-15 μM[2], respectively.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:MCF-7/ADR (P-gp-overexpressing, MRP-negative breast carcinoma cells)
-
Concentration:6 µg/mL (alone); 1 µg/mL (in presence of 25 nM actinomycin D)
-
Incubation Time:48 h
-
Result:Exhibited an IC20 of 6 µg/mL for intrinsic cytotoxicity.
Exhibited an EC50 of 1 µg/mL for reversing P-gp-mediated MDR in the presence of actinomycin D.
Was more effective at reversing P-gp-mediated MDR than all tested D-glucose mimetics of hapalosin.
-
Cell Line:HL-60/ADR (MRP-expressing, P-gp-negative promyelocytic leukemia cells)
-
Concentration:6 µg/mL (alone); 0.7 µg/mL (in presence of 2 nM vincristine)
-
Incubation Time:48 h
-
Result:Exhibited an IC20 of 6 µg/mL for intrinsic cytotoxicity.
Exhibited an EC50 of 0.7 µg/mL for reversing MRP-mediated MDR in the presence of vincristine.
Showed similar efficacy in reversing MRP-mediated MDR to select D-glucose mimetics.
Chemical Information
-
CAS No. 159542-04-8
-
Molecular Weight 489.64
-
Formula C28H43NO6
-
SMILES
CN(C([C@@H](OC([C@H]([C@H](OC(C[C@H]1O)=O)CCCCCCC)C)=O)C(C)C)=O)[C@H]1CC2=CC=CC=C2
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)